In a series of recent events, Sanofi has made significant headlines in the biotech space. The French multinational pharmaceutical company has demonstrated its commitment to affordability as it declared the price of its insulin products in the US will be capped at $35 per month. This is expected to significantly broaden patient access. Meanwhile, Sanofi's SAR446268 bagged fast track designation fortifying its place in the sphere of rare disease treatment. However, setbacks were faced due to anti-competitive conduct, resulting in a hefty payment of $177m ordered by a French court. The company also suffered fallout due to weak trial results for its eczema drug. With regard to investments, Sanofi is boosting its venture arm with a $625m infusion, gearing for growth in the biotech and digital health segments. But, moves like holding off UK R&D investments and FDA delay for its BTK inhibitor tolebrutinib have caused ripples. Despite these, the FDA granted approval to the company's Wayrilz, making it the first US BTK drug approved for immune thrombocytopenia. In addition, Sanofi and Regeneron’s Dupixent gets CHMP recommendation for treating chronic spontaneous urticaria.
Sanofi News Analytics from Thu, 03 Apr 2025 20:10:10 GMT to Sat, 27 Sep 2025 10:01:25 GMT -
Rating 5
- Innovation -5
- Information 6
- Rumor -7
